Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo Pharmaceutical has launched silodosin for the treatment of dysuria associated with benign prostatic hyperplasia in China.
Subscribe to our email newsletter
Silodosin works by inhibiting the alpha 1A-adrenergic receptor and relieving tension in the prostate, lessening pressure and reducing urethral resistance.
Kissei Pharmaceutical discovered silodosin, a selective alpha 1A-adrenoceptor antagonist existing mainly in the prostate.
Daiichi Sankyo and Kissei Pharmaceutical have been jointly marketing silodosin under the brand name, Urief, in Japan since May 2006.